Vaccine Composition
OwnerFrancois-Xavier Jacques BERTHET, Philippe Denoel +3inventors
InventorsFrancois-Xavier Jacques BERTHET, Philippe Denoel, Cecile Anne Neyt, Jan Poolman, Joelle Thonnard
Life of this patent
Estimating the term…
Abstract
The present invention provides a hyperblebbing non-typeable Haemophilus influenzae bacterium which has been genetically modified by either or both processes selected from a group consisting of: down-regulation of expression of one or more tol genes; and mutation of one or more gene(s) encoding a protein comprising a peptidoglycan-associated site to attenuate the peptidoglycan-binding activity of the protein.
Claims11
1-18. (canceled)
A hyperblebbing non-typeable Haemophilus influenzae bacterium which has been genetically modified by one or more processes selected from the group consisting of:
- (a) down-regulating expression of one or more Tol genes, and
- (b) attenuating the peptidoglycan-binding activity by mutation of one or more gene(s) encoding a protein comprising a peptidoglycan-associated site.
A hyperblebbing non-typeable Haemophilus influenzae bacterium which has been genetically modified by one or more processes selected from the group consisting of:
- (a) down-regulating expression of one or more Tol genes, and
- (b) attenuating the peptidoglycan-binding activity by mutation of ompP5.
A hyperblebbing non-typeable Haemophilus influenzae bacterium which has been genetically modified by (a) down-regulating expression of one or more Tol genes and (b) attenuating the peptidoglycan-binding activity by mutation of ompP5.
Dependencies are inferred from the claim text.